Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

134.31USD
22 Jul 2014
Price Change (% chg)

$-0.17 (-0.13%)
Prev Close
$134.48
Open
$134.56
Day's High
$134.71
Day's Low
$133.87
Volume
21,011
Avg. Vol
59,849
52-wk High
$145.20
52-wk Low
$108.45

BAYRY.PK

Chart for BAYRY.PK

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 1.39
Market Cap (Mil.): $110,941.20
Shares Outstanding (Mil.): 826.95
Dividend: 2.90
Yield (%): 2.15

Financials

  BAYRY.PK Industry Sector
P/E (TTM): 23.82 35.59 35.92
EPS (TTM): 5.65 -- --
ROI: 8.61 18.98 18.26
ROE: 16.97 19.75 19.14
Search Stocks

French lawmakers back Roche cancer drug as cheap eye treatment

* EU shift to Avastin a threat to Novartis, Bayer profits

08 Jul 2014

China approves Bayer deal to buy Dihon, other deals

SHANGHAI, July 4 - The Chinese Ministry of Commerce's anti-monopoly bureau has approved German drugmaker Bayer AG's deal for traditional Chinese medicine (TCM) drugmaker Dihon Pharmaceutical Group Co, in a raft of deals approved on Friday.

04 Jul 2014

UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands

* Coppertone, Dr. Scholl's draw interest after $14 bln deal

01 Jul 2014

CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands

(Corrects fourth paragraph to read "portfolio acquired from Merck", not "portfolio acquired by Merck")

01 Jul 2014

German manufacturing grows in June at weakest rate in eight months: PMI

BERLIN, - German manufacturing grew at the slowest rate in eight months in June, a survey showed on Tuesday, adding to signs that the expansion in Europe's largest economy lost momentum in the second quarter.

01 Jul 2014

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

27 Jun 2014

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT, June 27 - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

27 Jun 2014

New Issue-Bayer prices a dual tranche deal

Underlying govt bond Over the 3.25 pct January 2020 DBR

25 Jun 2014

Bayer bets on gene therapy with Dimension deal

FRANKFURT/LONDON - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.

23 Jun 2014

UPDATE 1-Bayer bets on gene therapy with Dimension deal

* UniQure, Bluebird Bio also working on gene therapies (Adds detail, background)

23 Jun 2014

Competitors

Earnings vs. Estimates

Search Stocks